AIImpactLab
9 impact clustersWork & marketsCognition & learningTechnical failuresPrivacySecurityEnvironmentLaw & informationSocial good & healthSystemic risk
Search the evidence

Find the signal.

Search titles, impact clusters, countries, organizations and the full text of every analysis.

5 stories found

Cognition & learningGlobal+1 clusters01

Aledavood et al., “AI-assisted fragment-based drug discovery of SARS-CoV-2 macrodomain binders validated by NMR and X-ray crystallography”

Researchers combined deep learning and molecular docking to design candidate binders for the SARS-CoV-2 Mac1 protein, then synthesized and experimentally confirmed selected compounds using NMR spectroscopy and X-ray crystallography. The resulting molecules improved on the original fragment hits, although their binding affinities—(K_D) values of 299–990 μM—indicate early-stage chemical starting points rather than therapeutic candidates.

2 min
Six protein biomarker dials converge on an experimental molecule above a lung scan while an unfinished trial path continues into shadow.
Social good & healthGlobal+2 clusters02

An AI-discovered lung drug shifted six aging clocks, not human lifespan

An experimental drug developed with AI has produced a result that is scientifically interesting and extremely easy to oversell. Rentosertib was designed for idiopathic pulmonary fibrosis, a progressive scarring disease of the lungs. Its target was identified with AI and its molecule was generated through an AI-driven discovery platform. Researchers analyzed protein data from 42 patients in a 12-week phase 2a trial and applied six independently developed proteomic aging clocks. All six estimated a reduction in predicted biological age among treated patients. Earlier trial results also showed a promising dose-related improvement in forced vital capacity, an important lung-function measure. Agreement across multiple clocks makes the signal less likely to be an artifact of one aging model. It does not prove that the drug extends life, reverses aging throughout the body, or is safe and effective as a longevity treatment. The cohort was small, the follow-up was short, the participants had a serious age-related disease, and improving inflammation or fibrosis can change proteins used by aging clocks. The Nature Biotechnology paper also discloses that several authors work for the company developing the drug and that its company leader is an author. The responsible interpretation is neither miracle nor dismissal. This is a hypothesis-generating biomarker result attached to a candidate that has advanced in clinical development. Larger, longer, independently scrutinized trials should prespecify aging endpoints and connect them with functional outcomes, safety, disease progression, and eventually survival. AI accelerated the discovery path. Biology still decides whether the claim survives.

5 min
A federal AI and supercomputing hub connecting health data, drug discovery, infrastructure materials, and scientific research.
Social good & healthUnited States+3 clusters03

A $5 billion federal push links AI to health, infrastructure and science

The U.S. government has committed more than $5 billion to expand the Genesis Mission, a multi-agency effort that combines federal datasets, Department of Energy supercomputers, research facilities, and AI tools. More than 15 agencies and 278 selected projects will target problems including chronic disease, pediatric cancer, drug discovery, resilient building materials, transportation maintenance, energy, manufacturing, agriculture, and national security.

3 min
Technical failuresGlobal+1 clusters04

Nature multi-agent scientific-discovery papers

A new Nature News & Views piece highlights two 2026 Nature papers showing AI agents moving from literature support toward hypothesis generation, experiment planning, and data analysis. One paper introduces Robin, a multi-agent system that generated hypotheses, proposed experiments, interpreted results, and identified therapeutic candidates for dry age-related macular degeneration; another introduces Google/DeepMind’s Gemini-based Co-Scientist, with affiliations including Stanford University School of Medicine and Imperial College London, and reports experimentally validated biomedical hypotheses including acute myeloid leukemia drug-repurposing and combination-therapy candidates.

2 min
Several luminous designed protein binders attach to a transparent molecular target above a physical laboratory assay tray.
Social good & healthGlobal+4 clusters05

Claude designs protein binders that survive wet-lab testing

Anthropic reports that Claude Opus 4.8 and Mythos Preview designed protein binders against 15 targets and succeeded against 14 after external laboratories produced and tested the designs. Reported hit rates ranged from 22.6 percent to 35.1 percent depending on the setup, above the 10 to 15 percent that Anthropic says is typical in current campaigns. The models orchestrated existing protein-design and folding tools with minimal human scientific guidance, producing 354 confirmed binders from 1,320 designs. This is a meaningful result because physical testing separates a scientific claim from a plausible-looking output. It is not a finished drug. Minibinders are an early design step, one target failed, additional characterization is planned, and the campaigns used substantial compute and specialist infrastructure. The same autonomy is dual-use, so Anthropic says its strongest biological capabilities remain restricted while it develops scientist access. The breakthrough and the control problem arrive together.

7 min